Access the full text.
Sign up today, get DeepDyve free for 14 days.
M. Khani, J. Hosseini, R. Mirfakhraie, Mohsen Habibi, E. Azargashb, F. Pouresmaeili (2019)
The value of the plasma circulating cell-free DNA concentration and integrity index as a clinical tool for prostate cancer diagnosis: a prospective case–control cohort study in an Iranian populationCancer Management and Research, 11
T. Chused, A. Steinberg, N. Talal (1972)
The clearance and localization of nucleic acids by New Zealand and normal mice.Clinical and experimental immunology, 12 4
S. Khier, Laura Lohan (2018)
Kinetics of circulating cell-free DNA for biomedical applications: critical appraisal of the literatureFuture Science OA, 4
Herng‐Ching Lin, L. Kao, Shiu-Dong Chung, Chung-Chien Huang, B. Shia, Chaoyuan Huang (2018)
Alzheimer’s disease is associated with prostate cancer: a population-based studyOncotarget, 9
H. Schwarzenbach, D. Hoon, K. Pantel (2011)
Cell-free nucleic acids as biomarkers in cancer patientsNature Reviews Cancer, 11
R. Chang, R. Kirby, B. Challacombe (2012)
Is there a link between BPH and prostate cancer?The Practitioner, 256 1750
S. Zelenay, Annemarthe Veen, Jan Böttcher, Kathryn Snelgrove, N. Rogers, S. Acton, P. Chakravarty, M. Girotti, R. Marais, S. Quezada, E. Sahai, C. Sousa (2015)
Cyclooxygenase-Dependent Tumor Growth through Evasion of ImmunityCell, 162
Y. Elshimali, Husseina Khaddour, Marianna Sarkissyan, Yanyuan Wu, J. Vadgama (2013)
The Clinical Utilization of Circulating Cell Free DNA (CCFDNA) in Blood of Cancer PatientsInternational Journal of Molecular Sciences, 14
C. Gosse, J. Pecq, P. Defrance, C. Paoletti (1965)
Initial degradation of deoxyribonucleic acid after injection in mammals.Cancer research, 25 6
Kimberly Tu, Bret Pearson, A. Alvarado (2012)
TORC1 is required to balance cell proliferation and cell death in planarians.Developmental biology, 365 2
C. Nunzio, G. Andriole, I. Thompson, S. Freedland (2015)
Smoking and Prostate Cancer: A Systematic Review.European urology focus, 1 1
W. Catalona, Deborah Smith, T. Ratliff, K. Dodds, D. Coplen, J. Yuan, J. Petros, G. Andriole (1991)
Measurement of prostate-specific antigen in serum as a screening test for prostate cancer.The New England journal of medicine, 324 17
V. Giri, J. Beebe-Dimmer (2016)
Familial prostate cancer.Seminars in oncology, 43 5
Bhargavi Duvvuri, C. Lood (2019)
Cell-Free DNA as a Biomarker in Autoimmune Rheumatic DiseasesFrontiers in Immunology, 10
W. Emlen, M. Mannik (1978)
Kinetics and mechanisms for removal of circulating single-stranded DNA in miceThe Journal of Experimental Medicine, 147
A. Bronkhorst, Vida Ungerer, S. Holdenrieder (2019)
The emerging role of cell-free DNA as a molecular marker for cancer managementBiomolecular Detection and Quantification, 17
R. Haque, S. Eeden, L. Wallner, K. Richert-Boe, B. Kallakury, Renyi Wang, S. Weinmann (2014)
Association of body mass index and prostate cancer mortality.Obesity research & clinical practice, 8 4
P. Delgado, B. Alves, Flávia Gehrke, R. Kuniyoshi, Marcelo Wroclavski, A. Giglio, F. Fonseca (2013)
Characterization of cell-free circulating DNA in plasma in patients with prostate cancerTumor Biology, 34
N. Lawrentschuk, L. Klotz (2010)
Active Surveillance for Favorable-Risk Prostate Cancer: A Short ReviewKorean Journal of Urology, 51
Y. Fuchs, H. Steller (2011)
Programmed Cell Death in Animal Development and DiseaseCell, 147
Young Yu, S. Byun, Sang Lee, S. Hong (2018)
Impact of Body Mass Index on Oncological Outcomes of Prostate Cancer Patients after Radical ProstatectomyScientific Reports, 8
S. Potter, A. Partin (2000)
Hereditary and familial prostate cancer: biologic aggressiveness and recurrence.Reviews in urology, 2 1
Debashish Sahay, M. Terry, Rachel Miller (2019)
Is breast cancer a result of epigenetic responses to traffic-related air pollution? A review of the latest evidence.Epigenomics, 11 6
R. Negrón, A. Vásquez, M. Nieves, Lourdes Guerrios, M. Irizarry-Ramírez (2010)
Body mass index affects the diagnosis and progression of prostate cancer in Hispanics.Ethnicity & disease, 20 1 Suppl 1
Alyssa Troeschel, E. Jacobs, W. Flanders, V. Stevens, T. Hartman, Lauren McCullough, T. Gansler, Ying Wang (2019)
Abstract LB-179: Pre- and post-diagnosis body mass index, weight change, and prostate cancer-specific mortality among prostate cancer survivors in the USEpidemiology
P. Gahan, M. Stroun (2010)
The virtosome—a novel cytosolic informative entity and intercellular messengerCell Biochemistry and Function, 28
N. Bezawada, M. Song, K. Wu, Raaj Mehta, G. Milne, S. Ogino, C. Fuchs, E. Giovannucci, A. Chan (2014)
Urinary PGE-M Levels Are Associated with Risk of Colorectal Adenomas and Chemopreventive Response to Anti-Inflammatory DrugsCancer Prevention Research, 7
W. Yue, Chung Yang, R. DiPaola, Xianglin Tan (2014)
Repurposing of Metformin and Aspirin by Targeting AMPK-mTOR and Inflammation for Pancreatic Cancer Prevention and TreatmentCancer Prevention Research, 7
M. Khani, F. Pouresmaeili, R. Mirfakhraie (2017)
Evaluation of Extracted Circulating Cell free DNA Concentration by Standard Nucleospin Plasma XS (NS) Kit Protocol Compared to its Modified ProtocolUrology & Nephrology Open Access Journal, 4
V. Labi, M. Erlacher (2015)
How cell death shapes cancerCell Death & Disease, 6
INTRODUCTION:Circulating cell-free DNA (ccfDNA) increases in some pathologic conditions like cancer. We aimed to investigate the correlation between some individual factors and the ccfDNA level in peripheral blood of Iranian in relation to prostate cancer.MATERIAL AND METHOD:30 patients with prostate cancer (PCa), 40 with benign prostate hyperplasia (BPH), and 30 controls were studied. Personal information, ccfDNA concentration, and the integrity index were assessed for the correlation between the disease and different factors. The results were statistically analyzed using SPSS software.RESULTS:In PCa group, no association was found between total ccfDNA, BMI, BPH background, non-cancerous diseases, medications, PCa length, and job (p-value > 0.05). But, total ccfDNA had statistical associations with weight, family history of cancer, and location (p-value < 0.05). No association was between the integrity of ccfDNA, weight, the background of BPH, and family history of cancer. But, the integrity of ccfDNA was significantly associated with BMI and PCa length (p-value < 0.05).In BPH group, no association between total ccfDNA or the integrity of ccfDNA and the assessed factors was obtained (p-value > 0.05). In the normal group, neither statistical association was found between total ccfDNA, weight, BMI, and job, nor between the integrity of ccfDNA, weight, BMI, non-cancerous disease, drug, job, and location (p-value > 0.05). But, a statistical association was found between the integrity of ccfDNA and family history of cancer in the recent group (Based on 95% CI and P-value less than 0.05).CONCLUSION:ccfDNA and its integrity as possible prostate cancer biomarkers under the influence of individuals’ physiological status are prone to the pathologic changes toward the disease. Further simultaneous study of the target groups could clarify this matter.
Human Antibodies – IOS Press
Published: Dec 9, 2020
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.